Recent Updates
Recently added Catalysts

Peripheral T-cell Lymphoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.2Buniverse median $1.20B
Allocated capital$411M$1.2B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank224/299crowding rank 227

Peripheral T-cell Lymphoma is uncontested. Corvus Pharmaceuticals (CRVS) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Soquelitinib in phase 3.

There is no public comparable to price it against. CRVS spreads its $1.2B market cap across 3 indications, so $411M of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$411M of allocated capital sits in Peripheral T-cell Lymphoma, ranking it 224th of 299 indications by the money committed to it.

Companies developing drugs for Peripheral T-cell Lymphoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CRVSCorvus PharmaceuticalsSoquelitinibPhase 33$1.2BNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Peripheral T-cell Lymphoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Peripheral T-cell Lymphoma has one competitor and a median of $1.2B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

T-cell Lymphoma1 company · $411M · median $1.2BUncontestedAdvanced Endometrial Cancer1 company · $410M · median $2.5BUncontestedRefractory Diffuse Large B-Cell Lymphoma1 company · $410M · median $2.5BUncontestedMultiple Myeloma3 companies · $421M · median $460MOrphan cornerChoroidal Melanoma1 company · $382M · median $764MUncontestedTriple Negative Metastatic Breast Cancer1 company · $448M · median $1.8BUncontestedEwing Sarcoma1 company · $448M · median $1.8BUncontestedChondrosarcoma1 company · $448M · median $1.8BUncontested

Peripheral T-cell Lymphoma pipeline questions

Which biotech companies are developing drugs for Peripheral T-cell Lymphoma?

Corvus Pharmaceuticals (CRVS, Soquelitinib, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Peripheral T-cell Lymphoma.

How advanced is the Peripheral T-cell Lymphoma pipeline?

Of the 1 clinical-stage programme in Peripheral T-cell Lymphoma, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Peripheral T-cell Lymphoma?

No. CRVS is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Peripheral T-cell Lymphoma, which is why the indication is classified as uncontested.

When is the next Peripheral T-cell Lymphoma catalyst?

The next dated catalyst in Peripheral T-cell Lymphoma is CRVS on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map